Indoco Remedies Reports Q3 FY25 Loss

  Published 10 months ago

Indoco Remedies, a pharmaceutical company manufacturing allopurinol (generic for Zyloprim) and APIs, reported a net loss of Rs 10.23 crore in Q3 FY25, a significant drop from the profit in Q3 FY24. Revenue also decreased by 18.61%.

  • Allopurinol treats high uric acid levels.
  • Indoco produces both APIs & formulations.
  • Q3 FY25 revenue was Rs 364.91 crore.

You might like these

CSB Bank Ratings Reaffirmed by CRISIL

Ircon International Wins ₹2.54B Railway Order

Govt to Auction Bonds on July 25

India's WPI Inflation Hits 14-Month Low in May 2025

Shakti Pumps QIP Allotment: Key Investors & Share Details

India’s Electronics Export Boom

Fasenra Approved for New Use in India

News that matters the most ⚡